Jump to content
Sclero Forums

Search the Community

Showing results for tags 'psa'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 14 results

  1. Low Doses of Etanercept (ETN) Can Be Effective to Maintain Remission in Psoriatic Arthritis (PsA) Patients. The main reasons that hinder the dosing interval increase in ETN in PsA patients are peripheral polyarthritis pattern and exacerbation of cutaneous manifestations. PubMed, J Clin Rheumatol, 2018 Apr;24(3):127-131. (Also see Psoriasis and Psoriatic Arthritis and Biologic Agents) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Psoriasis and arthritis sufferers have a higher risk of heart attacks and strokes, study finds. People with inflammatory arthritis and psoriasis should be closely monitored and given extra support to help prevent heart attack and strokes. Mail Online, 04/23/2018. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Subclinical impairment of myocardial and endothelial functionality in very early psoriatic (PsA) and rheumatoid arthritis patients: Association with vitamin D and inflammation. Disease activity was the main predictor of myocardial strain impairment and myocardial function was altered and associated with carotid intima-media thickness. Atherosclerosis, 03/06/2018. (Also see Symptoms and Complications of Rheumatoid Arthritis and Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Prevalence and type II diabetes–associated factors in psoriatic arthritis. Results suggested that diabetes was notably related to late–onset psoriasis and hypertension and the risk of diabetes ought to be evaluated carefully in subjects whose psoriasis begins after 40 years. PubMed, Clin Rheumatol, 02/22/2018. (Also see Psoriasis and Psoriatic Arthritis and Symptoms and Complications of Diabetes) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles
  5. Metabolic syndrome (MetS) in psoriatic arthritis (PsA): the interplay with cutaneous involvement. Evidences from literature and a recent cross–sectional study. In our study, the occurrence of MetS and mean levels of serum uric acid were higher in PsA patients with clinical evident psoriasis compared to sine psoriasis PsA. PubMed, Clin Rheumatol, 01/08/2018. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Use of biological drugs in patients with psoriasis (PsO) and psoriatic arthritis (PsA) in Italy: Results from the PSONG survey. Adalimumab could be the best therapeutic option over other anti–TNF agents for the treatment of PsO and PsA patients. PubMed, Dermatol Ther, 12/07/2017. (Also see Psoriasis and Psoriatic Arthritis and Biologic Agents) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Progress in genetic research on psoriatic arthritis. These studies have laid a foundation for risk prediction, diagnosis and drug development for psoriatic arthritis. PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2017 Aug 10;34(4):606-610. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Hyperuricemia is an independent risk factor for psoriatic arthritis (PsA) in psoriatic patients. Hyperuricemia may increase uric acid crystallization in and around joints, thereby inducing PsA in psoriatic subjects and it appears to be an independent risk factor for PsA. PubMed, J Dermatol, 07/10/2017. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. The problem in differentiation between psoriatic–related polyenthesitis and fibromyalgia (FMS). The unmet needs in the differentiation between FM and enthesitis in psoriatic disease patients are highlighted and critically evaluated in this article. PubMed, Rheumatology (Oxford), 04/05/2017. (Also see Fibromyalgia and Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Enhanced liver fibrosis test (ELF) in psoriasis (PSO), psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients: a cross–sectional comparison with procollagen–3 N–terminal peptide (P3NP). ELF may be superior to P3NP alone but further research should be done to validated ELF test susceptible for developing liver fibrosis for PSO, PSA and RA. PubMed, Br J Dermatol, 12/07/2016. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. The effectiveness of a real life dose reduction strategy for TNF inhibitors in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). In a real–world setting, 60% of individuals with severe AS and PsA who achieve low disease activity can successfully reduce the dose of TNF inhibitor therapy by a third for a mean of 1 year. PubMed, Rheumatology (Oxford), 06/28/2016. (Also see Ankylosing Spondylitis and Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. The proposed mechanisms for shared pathogenesis between psoriatic diseases and cardiovascular diseases are inflammation, insulin resistance, dyslipidemia, angiogenesis, oxidative stress, and endothelial dysfunction. PubMed, Rheumatol Int, 05/29/2016. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. New therapies for psoriasis and psoriatic arthritis. Secukinumab, an interleukin–17A antibody, has been approved for treatment of psoriasis and PsA in the United States. PubMed, Curr Opin Rheumatol, 2016 May;28(3):204-10. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  14. Differentiation between early rheumatoid and early psoriatic arthritis by the ultrasonographic (US) study of the synovio–entheseal complex of the small joints of the hands. The US involvement of synovio–entheseal complex and US extrasynovial features may be helpful in the differential diagnosis between early rheumatoid and early psoriatic arthritis. PubMed, Clin Exp Rheumatol, 03/03/2016. (Also see Diagnosis of Rheumatoid Arthritis and Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×